Stemona alkaloid derivative induce ferroptosis of colorectal cancer cell by mediating carnitine palmitoyltransferase 1
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Stemona alkaloid derivative (SA-11) induces ferroptosis by increasing acylcarnitine accumulation via CPT-1 regulation. This suggests a new therapeutic strategy for cancer by targeting fatty acid metabolism and enhancing reactive oxygen species (ROS) production.
Area Of Science
- Biochemistry
- Cell Biology
- Metabolic Disorders
Background
- Acylcarnitine accumulation is linked to metabolic disorders affecting fatty acid metabolism.
- No known molecules specifically induce ferroptosis by regulating acylcarnitine metabolism.
- Previous research identified Stemona alkaloid derivative (SA-11) as a ferroptosis inducer.
Purpose Of The Study
- To investigate the mechanism by which SA-11 induces ferroptosis, focusing on acylcarnitine metabolism.
- To identify specific molecular targets for enhancing ferroptosis in cancer treatment.
Main Methods
- Cell metabolomics studies to analyze acylcarnitine levels after SA-11 treatment.
- Measurement of carnitine palmitoyltransferase 1 (CPT-1) and CPT-2 levels.
- Assessment of reactive oxygen species (ROS) production in treated cells.
Main Results
- SA-11 treatment led to acylcarnitine accumulation.
- CPT-1 levels significantly increased, while CPT-2 levels remained unchanged.
- Exogenous acylcarnitine enhanced SA-11's ferroptosis-inducing ability and increased ROS levels.
Conclusions
- SA-11 induces ferroptosis by disrupting acylcarnitine metabolism through CPT-1 upregulation.
- Targeting acylcarnitine metabolism, specifically CPT-1, presents a potential therapeutic strategy for cancer.
- Enhanced ROS production is a key factor in SA-11-mediated ferroptosis induction.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...